



Astec LifeSciences Ltd.

Dated: 16th May, 2015

To,
The Department of Corporate Services
National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra, Mumbai-400051

Ref: "ASTEC"
Sub: Outcome of the Board Meeting.

Dear Sir,

This is to inform you that the Board of Directors at their meeting held on Saturday, 16th May, 2015 has:

- 1) Approved the Audited Financial Results (both Standalone & Consolidated) for the year ended 31st March, 2015. Please find enclosed herewith audited financials, Statement of Assets and Liabilities and Auditor's Report thereon for the period ended 31st March, 2015.
- 2) Management is pleased to recommend enhanced dividend of Rs.1.25/- per share (i.e. 12.50% on the face value of Rs.10/- each) for the period ended 31st March 2015 for the approval of the Shareholders at the ensuing Annual General Meeting, as compared to Re.1/- per share (i.e. 10% on the face value of Rs.10/- each) which was declared for the previous year.
- 3) Formulated and adopted "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information" (Code of Fair Disclosure) of the Company (under Regulation 8 of SEBI (Prohibition of Insider Trading) Regulations, 2015) with effect from 15th May, 2015. The same is published on the official website of the Company www.astecsl.com.
- 4) Formulated and approved "Code of Conduct for Prohibition of Insider Trading" (Code of Conduct) of the Company (under Regulation 9 of SEBI (Prohibition of Insider Trading) Regulations, 2015) with effect from 15th May, 2015. The same is published on the official website of the Company www.astecsl.com.

Please take the same on your records.

Thanking you,
Yours Sincerely,

FOR ASTEC LIFESCIENCES LIMITED

Tejal Jariwala
Company Secretary & Compliance Officer



Encl: A/a



Regd. Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001, India
Phone : +91-22- 2261 8212/ 6120 5600
Fax : +91-22- 2261 8289
E-mail : info@astecsl.com
Website : www.astecsl.com
CIN : L99999MH1994PLC076236



ASTEC LIFESCIENCES LTD
CIN No : L99999MH1904PLC076236
Regd. Office : 7th Floor, Ekte Square, 274, Peran Narayan Street, Fort, Mumbai - 400001.
Website: www.astecsl.com, Tel no 022-41205600, Fax: 022-22618289, E-mail id: info@astecsl.com
Audited Financial Results for the quarter/year ended 31st March, 2015

PART I	Sr. No	Particulars	STANDALONE					CONSOLIDATED				
			Rs. In Lacs (Except for per share data)					Rs. In Lacs (Except for per share data)				
			Quarter Ended		Year Ended			Quarter Ended		Year Ended		
			31/03/2015	31/12/2014	31/03/2014	31/03/2015	31/03/2014	31/03/2015	31/12/2014	31/03/2014	31/03/2015	31/03/2014
			(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1		Income from Operations										
	a)	Net Sales / Income from operations (Net of Excise Duty)	9,018.51	5,301.95	4,197.58	25,120.68	18,946.54	9,197.96	5,726.05	4,669.57	26,652.11	20,697.06
	b)	Other Operating Income	142.90	35.22	51.26	225.13	100.46	86.68	14.91	39.85	129.47	36.70
		Total Income from Operations (net)	9,161.42	5,337.17	4,248.84	25,345.82	19,047.00	9,284.64	5,740.96	4,709.42	26,781.58	20,733.75
2		Expenses										
	a)	Cost of materials consumed Including Utilities	5,517.67	3,710.83	2,814.23	16,981.87	14,224.49	5,671.70	3,894.55	2,860.78	18,183.33	15,745.31
	b)	Purchase of stock in trade										
	c)	Changes in inventories of finished goods and work in progress	828.09	(223.10)	(98.14)	241.20	(972.28)	768.35	(79.34)	233.72	72.40	(1185.00)
	d)	Employee benefits expenses	377.70	271.80	300.86	1,143.93	1,000.44	351.21	300.60	312.02	1,244.00	1,138.10
	e)	Depreciation and amortisation expenses	53.33	387.31	352.03	1,199.81	1,449.80	103.20	394.06	375.35	1,268.73	1,476.72
	f)	Other expenditure	646.01	373.80	444.43	1,625.31	1,298.01	608.43	405.42	459.56	1,777.30	1,461.35
		Total Expenses	7,422.80	4,520.63	3,813.41	21,192.11	17,000.46	7,502.88	4,915.30	4,241.44	22,545.76	18,636.48
3		Profit/ (Loss) from operations before other income, Finance Cost and Exceptional Items (1-2)	1,738.62	816.54	435.43	4,153.71	2,046.53	1,781.75	825.67	467.98	4,235.82	2,097.27
4		Other Income										
5		Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	1,738.62	816.54	435.43	4,153.71	2,046.53	1,781.75	825.67	467.98	4,235.82	2,097.27
6		Finance Costs	334.69	338.26	219.33	1,210.09	880.83	321.46	361.48	216.62	1,284.00	924.84
7		Profit after finance costs but before Exceptional Items (5-6)	1,403.93	478.28	216.09	2,943.62	1,165.70	1,460.29	464.19	251.36	2,951.82	1,172.43
8		Exceptional Items	1693.83	-	-	1,693.83	-	1,693.83	-	-	1,693.83	-
8		Profit / (Loss) from ordinary activities before tax	(289.90)	478.28	216.09	1,249.79	1,165.70	(233.54)	464.19	251.36	1,257.99	1,172.43
9		Tax Expense	74.66	104.66	66.69	410.98	246.20	81.37	104.92	70.30	419.35	249.81
10		Net Profit / (Loss) from ordinary activities after tax (8-9)	(364.56)	373.62	149.40	838.81	919.50	(314.91)	359.27	181.06	838.64	922.62
11		Extra ordinary / Prior Period Items (MAT Credit Entitlement)	(639.62)		21.98	(639.62)	57.46	(639.62)		21.98	(639.62)	57.46
12		Net Profit / (Loss) for the period (10 + 11)	275.06	373.62	127.43	1,478.43	862.05	324.71	359.27	159.08	1,478.26	865.16
13		Share of Profit / (Loss) of associates										
14		Minority Interest						0.03	0.28	(2.40)	0.72	(2.40)
15		Net Profit / (Loss) after taxes, minority interest and share of profit / (Loss) of associates (12-13-14)	275.06	373.62	127.43	1,478.43	862.05	324.68	358.99	161.48	1,477.54	867.56
16		Paid-up equity share capital (Face Value Rs.10/-)	1,945.51	1,852.91	1,852.91	1,945.51	1,852.91	1,945.51	1,852.91	1,852.91	1,945.51	1,852.91
17		Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	11,705.64	10,816.15	9,613.78	11,705.64	9,613.78	11,588.13	10,643.88	9,496.16	11,588.13	9,496.16
18		Earnings per share (Before Exceptional & Prior period Items) - Basic & Diluted	6.95	1.99	0.81	13.55	5.02	7.38	1.91	0.98	6.73	5.02
19		Earnings per share (After Exceptional & Prior period Items) - Basic & Diluted	1.44	1.99	0.69	7.91	4.71	1.74	1.91	0.86	7.91	4.74
PART II												
A	PARTICULARS OF SHAREHOLDING											
1	Public shareholding											
	- No of shares		8,698,075	7,772,150	7,772,150	8,698,075	7,772,150	8,698,075	7,772,150	7,772,150	8,698,075	7,772,150
	- Percentage of shareholding		44.71%	41.95%	41.95%	44.71%	41.95%	44.71%	41.95%	41.95%	44.71%	41.95%
2	Promoters and promoter group shareholding											
	a) Pledged / Encumbered											
	- No of shares		3,660,152	6,922,273	-	3,660,152	-	3,660,152	6,922,273		3,660,152	
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)		34.03%	64.35%	0.00%	34.03%	0.00%	34.03%	64.35%	0.00%	34.03%	0.00%

- Percentage of shares (as a % of the total share capital of the company)	18.81%	37.36%	0.00%	18.81%	0.00%	18.81%	37.36%	0.00%	18.81%	0.00%
b) Non-encumbered										
- No of shares	7,096,828	3,834,707	10,756,980	7,096,828	10,756,980	7,096,828	3,834,707	10,756,980	7,096,828	10,756,980
- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	65.97%	35.65%	100.00%	65.97%	100.00%	65.97%	35.65%	100.00%	65.97%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	36.38	20.69%	58.05%	36.38	58.05%	36.38	20.69%	58.05%	36.38	58.05%
PARTICULARS										
B INVESTOR COMPLAINTS										
Pending at the beginning of the quarter	0	0	0							
Received during the quarter	0	0	1							
Disposed of during the quarter	0	0	1							
Remaining unresolved at the end of the quarter	0	0	0							

Notes:

- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 16.05.2015.
- The above audited financial results have been reviewed by Statutory Auditor.
- Management is pleased to recommend enhanced dividend of Rs.1.25/- per share (i.e. 12.50% on the face value of Rs.10/- each) for the period ended 31st March 2015 for the approval of the Shareholders at the ensuing Annual General Meeting, as compared to Re.1/- per share (i.e. 10% on the face value of Rs.10/- each) which was declared for the previous year.
- Exceptional item represents amount paid at the time of filing of application to Settlement Commission in respect of discrepancies observed by DGCEI in the functioning of our EOU at B-17, MIDC, Mahad.
- Above Financial Results includes financials results of Behram Chemicals Pvt. Ltd. (65.63% subsidiary), Astec CropCare Pvt Ltd (100% Subsidiary of Astec) and Astec Europe Spri (50.10% subsidiary). The Financial Results of Comercializadora Agricola Agrostrachem Cia Ltda at Colombia (100% Subsidiary of Astec) are not included as the company has not commercialised its operation.
- Prior period item in respect of MAT Credit entitlement of earlier years now accounted in the books of accounts.
- The company has revised depreciation rates on Fixed Assets w.e.f. 01st April, 2014 as per useful life specified in schedule II of the companies Act, 2013 and depreciation charged in the last quarter of the year under review is the balancing amount between total depreciation for the full year & depreciation directly charged for the nine months period ended 31 st Dec. 2014.
- The company has only one reportable segment i.e. Agrochemicals.
- Figures of the previous year have been regrouped/rearranged, wherever necessary.
- Key standalone financial information of the company is given below :-

Particulars	Quarter Ended 31/03/2015	Quarter Ended 31/12/2014	Quarter Ended 31/03/2014	Year ended 31/03/2015	Year ended 31/03/2014
	(Audited)	(Un audited)	(Audited)	(Audited)	(Audited)
Net Sales / Income From operations (Net of Excise Duty)	9,018.51	5,301.95	4,197.58	25,120.68	18,946.54
Other Operating Income	142.90	35.22	51.26	225.13	100.46
Profit / (Loss) from ordinary activities before tax	1,403.93	428.28	216.09	2,943.62	1,165.70
Net Profit / (Loss) from ordinary activities after tax	(364.56)	323.61	149.41	838.81	919.50
Earnings per share (Before Extra-ordinary & Prior period items) - Basic & Diluted	6.95	1.59	0.81	13.55	5.02
Earnings per share (After Extra-ordinary & Prior period items) - Basic & Diluted	1.44	1.95	0.69	7.91	4.71

For Astec LifeSciences Limited

(Ashok V. Premnath)
Chairman & Managing Director
Saturday, 16 May, 2015



Statement of Liabilities and Assets as on 31st March 2015

	Standalone		Consolidated	
	As at	As at	As at	As at
	31/03/2015	31/03/2014	31/03/2015	31/03/2014
Equity and liabilities				
<i>Shareholders' funds</i>				
Share Capital	194,550,550	185,291,300	194,550,550	185,291,300
Reserves and surplus	1,170,563,722	961,378,278	1,158,813,340	949,616,390
	<u>1,365,114,272</u>	<u>1,146,669,578</u>	<u>1,353,363,890</u>	<u>1,134,907,690</u>
Minority Interest			508,977	437,387
<i>Non-current liabilities</i>				
Long-term borrowings	126,240,043	175,539,997	132,204,986	180,539,997
Deferred tax liabilities (net)	55,945,207	41,022,075	52,096,362	36,534,513
Other long term liabilities	291,018,513	307,292,365	297,681,922	307,292,365
Long-term Provisions	7,407,997	7,285,583	7,407,997	12,426,936
	<u>480,611,760</u>	<u>531,140,020</u>	<u>489,391,267</u>	<u>536,793,811</u>
<i>Current liabilities</i>				
Short-term borrowings	725,720,571	540,825,837	773,845,698	573,861,571
Trade payables	830,116,530	435,950,867	838,335,068	456,471,868
Other current liabilities	120,788,416	98,698,242	128,398,125	101,766,899
Short-term provisions	45,213,769	36,519,710	47,174,764	40,405,077
	<u>1,721,839,286</u>	<u>1,111,994,657</u>	<u>1,787,753,654</u>	<u>1,172,505,415</u>
Total	<u><u>3,567,565,318</u></u>	<u><u>2,789,804,255</u></u>	<u><u>3,631,017,788</u></u>	<u><u>2,844,644,304</u></u>
Assets				
<i>Non-current assets</i>				
Fixed assets				
Tangible / Intangible Assets	1,272,337,534	1,300,513,243	1,330,643,870	1,322,323,807
Capital work-in-progress	122,470,471	58,368,454	122,470,471	58,368,454
Non-current investments	9,981,395	9,991,795	237,800	148,200
Long-term loans and advances	192,288,344	113,814,169	193,300,370	114,826,195
	<u>1,597,077,744</u>	<u>1,482,687,661</u>	<u>1,646,652,511</u>	<u>1,495,666,656</u>
<i>Current assets</i>				
Current investments	917,436	534,960	917,436	684,960
Inventories	623,983,064	679,174,540	719,294,310	765,884,306
Trade receivables	976,090,704	444,246,193	1,048,305,436	513,936,102
Cash and bank balances	112,160,707	38,456,852	120,199,513	44,723,647
Short-term loans and advances	257,335,662	144,704,050	95,648,580	23,748,633
	<u>1,970,487,574</u>	<u>1,307,116,594</u>	<u>1,984,365,276</u>	<u>1,348,977,648</u>
Total	<u><u>3,567,565,318</u></u>	<u><u>2,789,804,255</u></u>	<u><u>3,631,017,788</u></u>	<u><u>2,844,644,304</u></u>

For Astec LifeSciences Limited

(Ashok V. Hiremath)
Chairman & Managing Director
Mumbai, May 16, 2015



C. A. P.M. KATHARIYA

B.Com., LLB., (Gen.), FCA

C. A. HEMANT S. MAHAVAR

B.Com., ACA

C.A. RONAK N. DHARNIDHARKA

B.Com., ACA

C.A. PRATIK M. CHOUDHARY

B.Com., ACA



SHAH & KATHARIYA
CHARTERED ACCOUNTANT

Room No. 6, Kermani Building, 4th Floor,
27, Sir P. M. Road, Fort, Mumbai - 400 001.
Ph. : 6631 5862 Fax : 2285 6615 R. : 2872 8803
Mobile : 98210 34665 / 99872 49694 / 705
E-mail : admin@shahkathariya.com
Web. : www.shahkathariya.com

Auditor's Report on the financial results of Astec Lifesciences Limited pursuant to Clause 41 of Listing Agreement

To the Board of Directors of Astec Lifesciences Limited

We have audited the accompanying annual financial results of **Astec Lifesciences Limited** ("the Company"), for the quarter ended 31 March 2015 and the year to date results for the period from 1 April 2014 to 31 March 2015, attached herewith, being submitted by the company pursuant to the requirement of Clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. Attention is drawn to the fact that the figures for the quarter ended 31 March 2015 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the current and previous financial year. Also the figures up to end of the third quarter for the current and previous financial year had only been reviewed and not subjected to audit.

Management's Responsibility for the Financial Results

These financial results have been prepared on the basis of the annual financial statements and reviewed quarterly financial results upto the end of the third quarter. Management is responsible for the preparation of these financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in the companies (Accounting Standards) Rules, 2006 which are notified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India and in compliance with clause 41 of the Listing Agreement.

This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.



C. A. P.M. KATHARIYA

B.Com., LLB., (Gen.), FCA

C. A. HEMANT S. MAHAVAR

B.Com., ACA

C.A. RONAK N. DHARNIDHARKA

B.Com., ACA

C.A. PRATIK M. CHOUDHARY

B.Com., ACA



SHAH & KATHARIYA
CHARTERED ACCOUNTANT

Room No. 6, Kermani Building, 4th Floor,
27, Sir P. M. Road, Fort, Mumbai - 400 001.
Ph. : 6631 5862 Fax : 2285 6615 R. : 2872 8803
Mobile : 98210 34665 / 99872 49694 / 705
E-mail : admin@shahkathariya.com
Web. : www.shahkathariya.com

**Auditor's Report on the financial results of Astec Lifesciences Limited pursuant to
Clause 41 of Listing Agreement(Continued)**

Auditor's Responsibility

Our responsibility is to express an opinion on these financial results based on our audit of the annual financial results. We conducted our audit in accordance with the auditing standards generally accepted in India. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s).

An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, these financial results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in these regard; and
- (ii) give a true and fair view of the net profit and other financial information for the year ended 31 March 2015.


Report on Other Legal and Regulatory Requirements

Further, we also report that we have, on the basis of the books of account and other records and information and explanation given to us by the management, verified the number of shares as well as percentage of shareholdings, in respect of aggregate amount of public shareholding as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

Place: Mumbai
Date: 16th May 2015



For Shah & Kathariya
Chartered Accountants
Firm Registration Number: 115171W


Per. P.M. Kathariya
(Partner)
Membership.No.031315